- Home
- SNTI vs IPDN Comparison
SNTI vs IPDN Comparison
Compare SNTI & IPDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- IPDN
- Stock Information
- Founded
- SNTI 2016
- IPDN 2003
- Country
- SNTI United States
- IPDN United States
- Employees
- SNTI N/A
- IPDN N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- IPDN EDP Services
- Sector
- SNTI Health Care
- IPDN Technology
- Exchange
- SNTI Nasdaq
- IPDN Nasdaq
- Market Cap
- SNTI 10.4M
- IPDN 11.1M
- IPO Year
- SNTI N/A
- IPDN 2013
- Fundamental
- Price
- SNTI $2.15
- IPDN $0.95
- Analyst Decision
- SNTI
- IPDN
- Analyst Count
- SNTI 0
- IPDN 0
- Target Price
- SNTI N/A
- IPDN N/A
- AVG Volume (30 Days)
- SNTI 16.0K
- IPDN 62.3K
- Earning Date
- SNTI 11-26-2024
- IPDN 11-14-2024
- Dividend Yield
- SNTI N/A
- IPDN N/A
- EPS Growth
- SNTI N/A
- IPDN N/A
- EPS
- SNTI N/A
- IPDN N/A
- Revenue
- SNTI N/A
- IPDN $7,005,632.00
- Revenue This Year
- SNTI $254.47
- IPDN N/A
- Revenue Next Year
- SNTI $169.66
- IPDN N/A
- P/E Ratio
- SNTI N/A
- IPDN N/A
- Revenue Growth
- SNTI N/A
- IPDN N/A
- 52 Week Low
- SNTI $1.52
- IPDN $0.42
- 52 Week High
- SNTI $7.43
- IPDN $3.01
- Technical
- Relative Strength Index (RSI)
- SNTI 44.66
- IPDN 63.43
- Support Level
- SNTI $2.12
- IPDN $0.66
- Resistance Level
- SNTI $2.40
- IPDN $0.77
- Average True Range (ATR)
- SNTI 0.16
- IPDN 0.10
- MACD
- SNTI 0.02
- IPDN -0.00
- Stochastic Oscillator
- SNTI 13.98
- IPDN 65.95
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About IPDN Professional Diversity Network Inc.
Professional Diversity Network Inc is engaged in providing access to networking, training, educational and employment services to its registered users. It has three operating segments: the Professional Diversity Network (PDN) segment, which includes online professional networking communities with career resources for diverse cultural groups and employers looking to hire members; and the National Association of Professional Women (NAPW) segment, which is a women-only professional networking organization, the RemoteMore segment. The company generates majority of its revenue from PDN Segment.